公开(公告)号：WO0193840A3

公开(公告)日：2002-08-08

申请号：PCT/EP0106397

申请日：2001-06-06

Applicant: BASF AG ,  GENESTE HERVE ,  KLING ANDREAS ,  LANGE UDO ,  SEITZ WERNER ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  HORNBERGER WILFRIED ,  LAUTERBACH ARNULF

Inventor： GENESTE HERVE ,  KLING ANDREAS ,  LANGE UDO ,  SEITZ WERNER ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  HORNBERGER WILFRIED ,  LAUTERBACH ARNULF

IPC: C07D223/10 ,  A61K31/55 ,  A61K31/5513 ,  A61K45/00 ,  A61K45/06 ,  A61P3/10 ,  A61P5/18 ,  A61P7/00 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P29/00 ,  A61P31/00 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P43/00 ,  C07D263/48 ,  C07D277/08 ,  C07D307/68 ,  C07D333/38 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07K5/023

CPC classification number: A61K45/06

Abstract: The invention relates to the use of cyclic compounds as ligands of integrin receptors, in particular as ligands of the alpha vss3 integrin receptor. The invention also relates to the novel compounds, to the use thereof and to pharmaceutical preparations which contain said compounds. Examples of said compounds include benzazepines, benzodiazepines and thieno[3,2-b]azepines, used for treating arteriosclerosis, rheumatoid arthritis, restenosis after vessel damage or stent implantation, angioplasty, acute kidney failure, microangiopathy associated with angiogenesis, diabetic angiopathy, thrombocyte-mediated vascular occlusion, arterial thrombosis, congestive heart-failure, myocardial infarct, apoplexy, cancer, osteoporosis, hypertension, psoriasis or viral, parasitic or bacterial diseases, inflammation, wound healing, hyperparathyroidism, Paget's bone disease, malignant hypercalcemia, or metastatic osteolytic lesions.

Abstract translation: 本发明涉及使用包含化合物作为整合素受体，特别是作为avB3整联的配体，该新颖化合物本身，它们的用途，以及药物制剂，这些化合物的配位体环状的。 作为例子苯并吖庚因，苯并二氮杂类和噻吩并[3,2-B]氮杂列出用于治疗动脉粥样硬化的，类风湿性关节炎，再狭窄血管损伤或支架植入术，血管成形术，急性肾功能衰竭，血管成形术，血管生成相关性微血管病，糖尿病性血管病，Blutplättchenvermitteltem血管闭合后 ，动脉血栓形成，充血性心脏衰竭，心肌梗死，中风，癌症，骨质疏松症，高血压，牛皮癣或病毒，寄生虫或细菌性疾病，炎症，疼痛肺，Hyperparathyroismus，佩吉特病，恶性高钙血症或转移性溶骨性病变。

公开(公告)号：WO0061551A3

公开(公告)日：2000-12-28

申请号：PCT/EP0002746

申请日：2000-03-29

Applicant: BASF AG ,  ZECHEL JOHANN CHRISTIAN ,  KLING ANDREAS ,  GENESTE HERVE ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  SADOWSKI JENS ,  HORNBERGER WILFRIED

Inventor： ZECHEL JOHANN-CHRISTIAN ,  KLING ANDREAS ,  GENESTE HERVE ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  SADOWSKI JENS ,  HORNBERGER WILFRIED

IPC: C07D239/36 ,  A61K31/505 ,  A61K45/00 ,  A61K45/06 ,  A61P3/14 ,  A61P7/02 ,  A61P9/10 ,  A61P9/12 ,  A61P13/12 ,  A61P17/02 ,  A61P17/06 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  C07D239/34 ,  C07D239/60 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D239/46 ,  C07D403/04

CPC classification number: C07D405/14 ,  A61K45/06 ,  C07D239/34 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14

Abstract: The invention relates to novel compounds that bind to integrin receptor ligands. The invention also relates to the production thereof, to their use as integrin receptor ligands and to their use for treating diseases, to pharmaceutical preparations that contain said compounds and to pharmaceutical preparations that contain at least one additional active compound.

Abstract translation: 本发明涉及一种结合于整联蛋白受体的新的化合物，它们的制备，它们作为整联的使用和用于治疗疾病的，含有这些化合物和含有至少一种其他活性化合物的药物制剂的药物制剂。

公开(公告)号：WO9722621A3

公开(公告)日：1998-02-26

申请号：PCT/EP9605518

申请日：1996-12-11

Applicant: BASF AG ,  AMBERG WILHELM ,  BARLOZZARI TERESA ,  BERNARD HARALD ,  BUSCHMANN ERNST ,  HAUPT ANDREAS ,  HEGE HANS GUENTHER ,  JANSSEN BERND ,  KLING ANDREAS ,  LIETZ HELMUT ,  RITTER KURT ,  ULLRICH MARTINA ,  WEYMANN JUERGEN ,  ZIERKE THOMAS

Inventor： AMBERG WILHELM ,  BARLOZZARI TERESA ,  BERNARD HARALD ,  BUSCHMANN ERNST ,  HAUPT ANDREAS ,  HEGE HANS-GUENTHER ,  JANSSEN BERND ,  KLING ANDREAS ,  LIETZ HELMUT ,  RITTER KURT ,  ULLRICH MARTINA ,  WEYMANN JUERGEN ,  ZIERKE THOMAS

IPC: A61K38/00 ,  A61K31/00 ,  A61K38/08 ,  A61P35/00 ,  A61P35/02 ,  C07K1/00 ,  C07K7/06

CPC classification number: A61K38/08

Abstract: Novel peptides of the following formula (I): R1R2N-CHX-CO-A-B-D-E-(G)¿s?-K in which R?1, R2¿, A, B, D, E, G, K, X, and s have the meanings stated in the description, and the preparation thereof are described. The novel peptides have an antineoplastic effect.

公开(公告)号：WO0124827A3

公开(公告)日：2002-05-10

申请号：PCT/EP0009671

申请日：2000-10-02

Applicant: BASF AG ,  AMBERG WILHELM ,  KLING ANDREAS ,  HORNBERGER WILFRIED

Inventor： AMBERG WILHELM ,  KLING ANDREAS ,  HORNBERGER WILFRIED

IPC: A61K38/00 ,  A61K45/00 ,  A61K45/06 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07D239/34 ,  C07D263/34 ,  C07D277/48 ,  C07D307/68 ,  C07D333/38 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07K5/02

CPC classification number: C07D263/34 ,  A61K38/00 ,  A61K45/06 ,  C07D239/34 ,  C07D277/48 ,  C07D307/68 ,  C07D333/38 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07K5/0202

Abstract: The invention relates to the use of an endothelin blocker in combination with an alpha v beta 3 integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an alpha v beta 3 integrin receptor antagonist, for the treatment or prevention of cardiovascular disorders, particularly for the treatment or prevention of restenosis after vessel injury or revascularisation treatment and to the pharmaceutical composition itself.

Abstract translation: 本发明涉及内皮素阻滞剂与αvβ3整联蛋白受体拮抗剂组合用于治疗或预防疾病，特别是包含内皮素阻断剂和αvβ3整联蛋白受体的药物组合物的使用 拮抗剂，用于治疗或预防心血管疾病，特别是用于治疗或预防血管损伤或血运重建治疗后的再狭窄以及药物组合物本身。

公开(公告)号：WO9809953A3

公开(公告)日：1998-10-29

申请号：PCT/EP9704688

申请日：1997-09-02

Applicant: BASF AG ,  AMBERG WILHELM ,  JANSEN ROLF ,  KLING ANDREAS ,  KLINGE DAGMAR ,  RIECHERS HARTMUT ,  HERGENROEDER STEFAN ,  RASCHACK MANFRED ,  UNGER LILIANE

Inventor： AMBERG WILHELM ,  JANSEN ROLF ,  KLING ANDREAS ,  KLINGE DAGMAR ,  RIECHERS HARTMUT ,  HERGENROEDER STEFAN ,  RASCHACK MANFRED ,  UNGER LILIANE

IPC: A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61P9/04 ,  A61P9/08 ,  A61P9/12 ,  A61P43/00 ,  C07C59/66 ,  C07C69/734 ,  C07D239/34 ,  C07D239/52 ,  C07D239/60 ,  C07D239/70 ,  C07D491/04 ,  C07D491/048

CPC classification number: C07D239/70 ,  C07C59/66 ,  C07C69/734 ,  C07D239/34 ,  C07D239/52 ,  C07D239/60 ,  C07D491/04

Abstract: Carboxylic acid derivatives have the formula (I), in which R1 stands for tetrazole or a group (a); R2 stands for hydrogen, hydroxy, NH¿2?, NH(C1-c4-alkyl), N(C1-C4-alkyl)2, halogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, C1-C4-halogenalkyl, C1-C4-alkoxy, C1-C4-halogenalkoxy or C1-C4-alkylthio, or CR?2¿ is linked with CR10, as indicated below, into a 5- or 6-membered ring; X stands for nitrogen or methine; Y stands for nitrogen or methine; Z stands for nitrogen or CR10, wherein R10 is hydrogen or C¿1?-C4-alkyl or CR?10¿ forms together with CR?2 or CR3¿ an optionally substituted 5- or 6-membered alkylene or alkenylene ring, and wherein one or more methylene groups can be substituted by oxygen, sulphur, -NH or -N(C¿1?-C4-alkyl); R?3¿ stands for hydrogen, hydroxy, NH¿2?, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, halogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkinyl, C1-C4-hydroxyalkyl, C1-C4-halogenalkyl, C1-C4-alkoxy, C1-C4-halogenalkoxy, C1-C4-alkylthio; or CR?3¿ is linked to CR10 as indicated above into a 5- or 6-membered ring, R?4 and R5¿ (which may be identical or different) stand for optionally substituted phenyl or naphthyl, or for phenyl or naphthyl which are linked to each other at the ortho-position by a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulphur atom or an SO¿2?, NH or N-alkyl group; optionally substituted C3-C8-cycloalkyl; R?6¿ stands for optionally substituted C¿3?-C8-cycloalkyl; optionally substituted phenyl or naphthyl, a 5- or 6-membered, optionally substituted heteroaromatic compound containing one to three nitrogen atoms and/or one sulphur or oxygen atom; W stands for sulphur or oxygen; Q is a spacer with a length that corresponds to a C2-C4 chain. Also disclosed are the physiologically tolerable salts of these compounds, as well as their pure enantiomer and diastereoisomer forms, their preparation and use as mixed ETA/ETB-receptor antagonists.

公开(公告)号：WO0214320A2

公开(公告)日：2002-02-21

申请号：PCT/EP0109224

申请日：2001-08-09

Applicant: BASF AG ,  GENESTE HERVE ,  KLING ANDREAS ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  HORNBERGER WILFRIED

Inventor： GENESTE HERVE ,  KLING ANDREAS ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  HORNBERGER WILFRIED

IPC: C07D401/12 ,  A61K31/55 ,  A61K45/00 ,  A61K45/06 ,  A61P3/10 ,  A61P3/14 ,  A61P5/18 ,  A61P7/02 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P13/12 ,  A61P17/02 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P19/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P35/04 ,  A61P41/00 ,  A61P43/00 ,  C07D277/28 ,  C07D403/12 ,  C07D471/04 ,  C07D487/04

CPC classification number: A61K45/06

Abstract: The invention relates to novel compounds which bind to integrin receptors, in particular as ligands for the alpha V beta 3 integrin receptor, the use thereof and pharmaceutical preparations containing said compounds.

Abstract translation: 本发明涉及一种结合于整联蛋白受体，它们作为整联蛋白受体配体，特别是作为阿尔法v的β3整联蛋白受体配体，它们的使用，以及含有这些化合物的药物制剂的新化合物。

公开(公告)号：WO0110847A8

公开(公告)日：2001-12-06

申请号：PCT/EP0007440

申请日：2000-08-01

Applicant: BASF AG ,  KLING ANDREAS ,  GENESTE HERVE ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  HOLZENKAMP UTA ,  MACK HELMUT ,  SADOWSKI JENS ,  HORNBERGER WILFRIED ,  LAUX VOLKER

Inventor： KLING ANDREAS ,  GENESTE HERVE ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  HOLZENKAMP UTA ,  MACK HELMUT ,  SADOWSKI JENS ,  HORNBERGER WILFRIED ,  LAUX VOLKER

IPC: A61K31/4402 ,  A61K31/55 ,  A61K31/5513 ,  A61P3/14 ,  A61P5/18 ,  A61P7/02 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P13/12 ,  A61P17/02 ,  A61P17/06 ,  A61P19/00 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07D213/74 ,  C07D223/20 ,  C07D243/38 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D495/14 ,  C07D213/73 ,  C07D491/04

CPC classification number: C07D401/06 ,  C07D223/20 ,  C07D243/38 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D495/14

Abstract: The invention relates to novel compounds of formula (I) which bind to integrin receptors, wherein G and L have the following meaning: L is a structural element of formula IL, wherein T represents a COOH group or a radical that can be hydrolyzed to obtain COOH and U- represents (XL)a-(CRL RL )b-, -CRL =CRL -, ethylene or =CRL -, wherein a is 0 or 1; b is 0, 1 or 2; XL represents CRL RL , NRL , oxygen or sulfur and G is a structural element of formula IG, wherein the insertion of structural element G can occur in both orientations and XO represents nitrogen or CRG . The invention also relates to the production of said compounds and to their use as medicaments.

Abstract translation: 本发明涉及式（I）的化合物BGL（I）其中G和L具有以下含义：L式IL -UT（IL），其中T是基团COOH或水解性与COOH和-U-自由基的结构元件 - （XL ）α-（CRL <1> RL <2>）b -CRL <1> CRL <1> CRL <2> - ，亚乙炔基或= CRL <1> - 表示，其中a是0或1，b 0,1或2 XL CRL <3> RL <4> NRL <5>，氧或硫，G是式LG（IG）的结构元件的结构元件G能够以两个方向和XG进行的，其中，所述安装是氮或CRG < 1与整联蛋白受体结合，它们的产生和它们作为药物的用途。

公开(公告)号：WO0110847A3

公开(公告)日：2001-11-01

申请号：PCT/EP0007440

申请日：2000-08-01

Applicant: BASF AG ,  KLING ANDREAS ,  GENESTE HERVE ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  HOLZENKAMP UTA ,  MACK HELMUT ,  SADOWSKI JENS ,  HORNBERGER WILFRIED ,  LAUX VOLKER

Inventor： KLING ANDREAS ,  GENESTE HERVE ,  LANGE UDO ,  LAUTERBACH ARNULF ,  GRAEF CLAUDIA ISABELLA ,  SUBKOWSKI THOMAS ,  HOLZENKAMP UTA ,  MACK HELMUT ,  SADOWSKI JENS ,  HORNBERGER WILFRIED ,  LAUX VOLKER

IPC: A61K31/4402 ,  A61K31/55 ,  A61K31/5513 ,  A61P3/14 ,  A61P5/18 ,  A61P7/02 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P13/12 ,  A61P17/02 ,  A61P17/06 ,  A61P19/00 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07D213/74 ,  C07D223/20 ,  C07D243/38 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D495/14 ,  C07D213/73 ,  C07D491/04

CPC classification number: C07D401/06 ,  C07D223/20 ,  C07D243/38 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D495/14

Abstract: The invention relates to novel compounds of formula (I) which bind to integrin receptors, wherein G and L have the following meaning: L is a structural element of formula IL, wherein T represents a COOH group or a radical that can be hydrolyzed to obtain COOH and U- represents (XL)a-(CRL RL )b-, -CRL =CRL -, ethylene or =CRL -, wherein a is 0 or 1; b is 0, 1 or 2; XL represents CRL RL , NRL , oxygen or sulfur and G is a structural element of formula IG, wherein the insertion of structural element G can occur in both orientations and XO represents nitrogen or CRG . The invention also relates to the production of said compounds and to their use as medicaments.

Abstract translation: 本发明涉及式（I）的化合物BGL（I）其中G和L具有以下含义：L式IL -UT（IL），其中T是基团COOH或水解性与COOH和-U-自由基的结构元件 - （XL ）α-（CRL <1> RL <2>）b -CRL <1> CRL <1> CRL <2> - ，亚乙炔基或= CRL <1> - 表示，其中a是0或1，b 0,1或2 XL CRL <3> RL <4> NRL <5>，氧或硫，G是式LG（IG）的结构元件的结构元件G能够以两个方向和XG进行的，其中，所述安装是氮或CRG < 1>结合至整联蛋白受体，它们的制备和它们作为药物的用途。

公开(公告)号：WO0118032A2

公开(公告)日：2001-03-15

申请号：PCT/US0024658

申请日：2000-09-08

Applicant: BASF AG ,  UNIV ARIZONA ,  PETIT GEORGE R ,  SRIRANGAM JAYARAM K ,  WILLIAMS MICHAEL D ,  DURKIN KIERAN P M ,  BARLOZZARI TERESA ,  KLING ANDREAS ,  JANSSEN BERND ,  HAUPT ANDREAS

Inventor： PETIT GEORGE R ,  SRIRANGAM JAYARAM K ,  WILLIAMS MICHAEL D ,  DURKIN KIERAN P M ,  BARLOZZARI TERESA ,  KLING ANDREAS ,  JANSSEN BERND ,  HAUPT ANDREAS

IPC: C07K5/02 ,  C07K7/02 ,  C07K5/00

CPC classification number: C07K5/0202 ,  C07K5/0205 ,  C07K7/02

Abstract: The present invention provides compounds of formula (I) where R1-R5 are each, independently, a hydrogen atom or a normal or branched C1-C6-alkyl group; A is a methionyl, phenylalanyl or phenylglycyl residue; n is 0 or 1; R6 is a hydrogen atom; and R7 is a carbocyclic group, an aromatic group, a C1-C4-alkyl group, a pyridylalkyl group or a heterocyclic group. In another embodiment, R6 is benzyl or -C(O)OR8, where R8 is a C1-C6-alkyl group, and R7 is a heteroaromatic group, such as a 2-thiazolyl group.

Abstract translation: 本发明提供式（I）化合物，其中R 1 -R 5各自独立地为氢原子或正
或支链C 1 -C 6烷基; A是甲硫氨酰基，苯丙氨酰或苯基甘氨酰残基; n为0或1; R6是氢原子; 并且R 7是碳环基，芳基，C 1 -C 4 - 烷基，吡啶基烷基或杂环基。 在另一个实施方案中，R 6为苄基或-C（O）OR 8，其中R 8为C 1 -C 6烷基，R 7为杂芳族基团，例如2-噻唑基。

公开(公告)号：WO0061608A3

公开(公告)日：2001-01-11

申请号：PCT/EP0002710

申请日：2000-03-28

Applicant: BASF AG

Inventor： HILLEN HEINZ ,  SCHMIDT MARTIN ,  MACK HELMUT ,  SEITZ WERNER ,  HAUPT ANDREAS ,  ZECHEL JOHANN-CHRISTIAN ,  KLING ANDREAS

IPC: C12N9/99 ,  A61K38/00 ,  A61P1/04 ,  A61P1/18 ,  A61P5/14 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P37/02 ,  C07B43/00 ,  C07D401/12 ,  C07K5/06 ,  C07K5/065 ,  C07K5/062 ,  A61K38/05 ,  C07D409/12 ,  C07K5/068 ,  C07K5/072 ,  C07K5/078

CPC classification number: C07D401/12 ,  A61K38/00 ,  C07B43/00 ,  C07K5/06078

Abstract: The invention relates to peptidic substances, to the production of said substances and to their use as complement inhibitors. In particular, the invention relates to substances with a guanidine or amidine radical as the terminal group, especially inhibitors of the complement proteases C1s and C1r.

Abstract translation: 本发明涉及肽的物质，它们的制备和它们作为补体抑制剂的用途。 具体而言，存在与一个胍或脒基作为末端基团的物质。 特别地，本发明涉及的C1s和C1R Komplementproteasen的抑制剂。